Boehringer Ingelheim and Envisagenics have entered into a research collaboration and option agreement aimed at validating tumour-specific targets for the development of precision therapies in solid ...

Novo is shaping a future beyond its Wegovy franchise as CEO Maziar Mike Doustdar looks to turn the drugmaker’s fortunes around.

Made Scientific has acquired an 85,000ft² cell therapy manufacturing facility in Pennsylvania, US, from National Resilience.

Obicetrapib is being developed as a low-dose, oral CETP inhibitor for lowering LDL cholesterol in patients unresponsive to treatments. Credit: PeopleImages / Shutterstock.com. The European Commission ...

Telix’s board has approved the transaction, and shareholders holding more than 90% of ITM shares had approved it at signing. Credit: Samuel Boivin / Shutterstock.com. Australia-based Telix ...

The biosimilar candidate is intended to reference Hemlibra (emicizumab), which addresses haemophilia A, a genetic disorder. Credit: angellodeco/Shutterstock.com ...

The deal reflects a growing interest from big pharma in the compounds that bridge the gap between small molecules and biologics.

WuXi XDC Cayman is to provide Ona Therapeutics with an exclusive global licence to its WuXiTecan-2 platform to develop an ADC candidate.

Novo will harness Anthropic’s AI assistant Claude to accelerate research and development (R&D) activities, as the drugmaker looks to regain its once-dominant position at the fro ...

GF-CART01 has shown positive clinical trial data in Taiwan. Credit: ultramansk / Shutterstock.com. Cellares and GenomeFrontier Therapeutics have announced a collaboration to assess automated ...